
Associate Professor
Department of Biotechnical and Clinical Laboratory Sciences
Jacobs School of Medicine & Biomedical Sciences
Glia - Physiology & Pathophysiology; Lysosomal Storage Diseases; Myelin Diseases; Neurodevelopmental Disorders
Krabbe disease (KD), or globoid cell leukodystrophy, is a fatal neurodegenerative lysosomal storage disorder caused by a deficiency in galactosylceramidase (GALC), impacting both the central and peripheral nervous systems. Early-infantile KD typically manifests within the first few months of life with severe irritability, muscle rigidity, and rapid motor decline, inevitably progressing to terminal clinical decay within months. Currently, no cure exists.
Our understanding of KD pathogenesis remains limited, largely constrained by clinical observation and spontaneous animal models. While hematopoietic stem cell transplantation (HSCT) can partially attenuate disease progression, its efficacy is strictly limited to pre-symptomatic intervention. This therapy relies on cross-correction—the mechanism by which stem cell derivatives secrete functional GALC that is internalized by recipient glia via mannose-6-phosphate receptors. However, critical questions remain regarding the in vivo efficiency of cross-correction, the precise cell types requiring restoration, and the developmental window during which intervention must occur. Furthermore, while GALC deficiency causes toxic accumulation of the lysolipid psychosine—driving oligodendrocyte, Schwann cell, and neuronal death—the relative contribution of psychosine toxicity, its primary cellular sources, and the precise cascade of pathogenic events remain unresolved.
To address these critical gaps, we generated a novel conditional Galc floxed mouse allele. Utilizing targeted in vivo and in vitro conditional knockout models, we are elucidating the cell-autonomous and non-cell-autonomous mechanisms driving KD, as well as the mechanistic constraints of HSCT cross-correction. By dissecting both the primary loss-of-function defects and downstream secondary pathogenic pathways, our goal is to identify novel therapeutic targets for Krabbe disease and related neurodegenerative and demyelinating leukodystrophies.